Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Chairman P Roy Vagelos sold 9,295 shares of the firm’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $458.14, for a total value of $4,258,411.30. Following the completion of the sale, the chairman now owns 414,156 shares of the company’s stock, valued at $189,741,429.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) traded down 0.12% on Friday, hitting $455.17. The company had a trading volume of 475,520 shares. Regeneron Pharmaceuticals Inc has a one year low of $325.35 and a one year high of $464.40. The stock has a 50 day moving average of $408.39 and a 200-day moving average of $385.04. The stock has a market capitalization of $48.05 billion, a PE ratio of 55.10 and a beta of 1.44. Regeneron Pharmaceuticals also was the target of unusually large options trading on Tuesday. Stock investors bought 389 put options on the company. This represents an increase of 232% compared to the typical daily volume of 117 put options.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 EPS for the quarter, topping the Zacks’ consensus estimate of $2.50 by $0.42. The business had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.30 billion. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. Regeneron Pharmaceuticals’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period last year, the company posted $2.57 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals Inc will post $12.68 EPS for the current year.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals Inc (REGN) Chairman Sells $4,258,411.30 in Stock” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/05/26/regeneron-pharmaceuticals-inc-regn-chairman-sells-4258411-30-in-stock.html.

Several research firms have recently weighed in on REGN. Leerink Swann set a $448.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, February 11th. BMO Capital Markets boosted their target price on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research note on Monday, May 15th. Cowen and Company reaffirmed a “hold” rating and set a $380.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, May 15th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Regeneron Pharmaceuticals in a research report on Thursday. Finally, Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price target on the stock in a research report on Thursday, April 27th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have given a buy rating to the company. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $432.21.

Hedge funds have recently modified their holdings of the company. Princeton Capital Management Inc. raised its stake in shares of Regeneron Pharmaceuticals by 14.6% in the third quarter. Princeton Capital Management Inc. now owns 2,235 shares of the biopharmaceutical company’s stock worth $899,000 after buying an additional 284 shares during the period. Biondo Investment Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 402.0% in the third quarter. Biondo Investment Advisors LLC now owns 11,470 shares of the biopharmaceutical company’s stock worth $4,611,000 after buying an additional 9,185 shares during the period. Sei Investments Co. raised its stake in shares of Regeneron Pharmaceuticals by 3.6% in the third quarter. Sei Investments Co. now owns 197,217 shares of the biopharmaceutical company’s stock worth $79,285,000 after buying an additional 6,801 shares during the period. Boston Common Asset Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 26.5% in the third quarter. Boston Common Asset Management LLC now owns 11,592 shares of the biopharmaceutical company’s stock worth $4,660,000 after buying an additional 2,431 shares during the period. Finally, Ngam Advisors L.P. acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $28,309,000. Institutional investors and hedge funds own 68.83% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

12 Month Chart for NASDAQ:REGN

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.